Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27703735 | 0.91 | MEN1 (0.83) | GAAMEN1KMT2AALDH1A1HTT | |
| SCHEMBL7354598 | 0.90 | ALDH1A1 (0.64) | GAAMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL7350528 | 0.85 | ALDH1A1 (0.63) | KMT2AALDH1A1CYP2C19HTTTSHR | |
| SCHEMBL2109312 | 0.85 | GAA (0.63) | GAAMEN1KMT2AALDH1A1CYP2C19 | |
| SCHEMBL7353744 | 0.85 | GAA (0.75) | GAAMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL93948 | 0.85 | GAA (0.75) | GAAMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL7293964 | 0.84 | GAA (0.58) | GAAMEN1KMT2AALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL1128739 | 0.83 | GAA (0.72) | GAAMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL2942358 | 0.82 | MEN1 (0.96) | GAAMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL2808337 | 0.82 | L3MBTL1 (0.67) | ALDH1A1L3MBTL1TSHRTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | claimed |
| US-20030171333-A1 | Pharmaceutical composition containing at least a polymer combined with or conjugated to at least a phenylalkylcarboxylic acid salt, conjugate polymers and uses thereof | BIODEX (FR) | 2003-09-11 | — | — | US | claimed |
| EP-1289515-A1 | PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST A POLYMER ASSOCIATED OR CONJUGATED WITH AT LEAST A PHENYLALKYLCARBOXYLIC ACID SALT, CONJUGATE POLYMERS AND USES THEREOF | BIODEX (FR) | 2003-03-12 | — | — | EP | claimed |
| WO-2001091742-A1 | PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST A POLYMER ASSOCIATED OR CONJUGATED WITH AT LEAST A PHENYLALKYLCARBOXYLIC ACID SALT, CONJUGATE POLYMERS AND USES THEREOF | BIODEX (FR) | 2001-12-06 | — | — | WO | claimed |
| US-5227401-A | ETHYNYL ALANINE AMINO DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G. D. SEARLE & CO. (US) | 1993-07-13 | — | — | US | claimed |
| US-5223535-A | Renin inhibitors | G. D. SEARLE & CO. (US) | 1993-06-29 | — | — | US | claimed |
| WO-2025121320-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR POLYCYSTIC KIDNEY DISEASE | 国立大学法人山口大学 | 2025-06-12 | — | — | WO | disclosed |
| WO-2021252640-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-8822452-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2014-09-02 | — | — | US | disclosed |
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-8524894-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-20080103311-A1 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-7312333-B2 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| EP-0554400-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-08-11 | — | — | EP | disclosed |
| EP-0512415-A2 | Process for the enantioselective synthesis of 2(R)-benzyl succanamide derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-11-11 | — | — | EP | disclosed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008701-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008698-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008688-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008699-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | GAA 473/4885MEN1 808/4885KMT2A 3688/4885 |
| US-20080103311-A1 | Retroviral protease inhibitors | PREP, DNPEP, SERPINB1 | GAA 126/4885MEN1 4153/4885KMT2A 1293/4885 |
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | GAA 751/4885MEN1 827/4885KMT2A 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.